|
Predicting long term outcomes following radical prostatectomy using a validated pathology-based multimodal artificial intelligence biomarker. |
| |
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Dendreon; Janssen; LynxDx; Merck; Pfizer; Tempus; Veracyte; Verana Health |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
|
Stock and Other Ownership Interests - Artera |
| |
|
No Relationships to Disclose |
| |
|
|
Stock and Other Ownership Interests - Artera |
| |
|
|
Stock and Other Ownership Interests - Artera |
| |
|
Employment - ArteraAI; Flatiron Health |
Stock and Other Ownership Interests - Deep Blue Medical; Galaxy Diagnostics; Lumata Health; mPATH; Roche; SonoVascular; VitriVax |
Consulting or Advisory Role - Agilix Health |
| |
|
Employment - Artera, Inc. |
Stock and Other Ownership Interests - Artera, Inc. |
| |
|
|
Stock and Other Ownership Interests - Artera |
| |
|
|
Stock and Other Ownership Interests - Artera |
| |
|
Employment - Artera Inc., Los Altos, CA |
Stock and Other Ownership Interests - Artera Inc., Los Altos, CA |
| |
|
Stock and Other Ownership Interests - Artera; Bluestar Genomics; Serimmune |
Consulting or Advisory Role - Artera; Astellas Pharma; Bayer; BlueStar Genomics; Bristol Myers Squibb; Bristol Myers Squibb (BMS); Exact Sciences; Foundation Medicine; Janssen Biotech; Myovant Sciences; Novartis; POINT Biopharma; Roivant; SerImmune; Tempus; Varian Medical Systems |
Research Funding - Zenith Epigenetics |
| |
|
Research Funding - Bristol Myers Squibb Foundation (Inst); Intuitive Surgical (Inst) |
| |
|
No Relationships to Disclose |
| |
|
Stock and Other Ownership Interests - Nutcracker Therapeutics, Inc.; Nutcracker Therapeutics, Inc. |
Honoraria - BIOPHARM; Exact Sciences |
Consulting or Advisory Role - Alessa Therapeutics; Francis Medical; Insightec; Johnson & Johnson/Janssen; Progenics |
Research Funding - Intuitive Surgical (Inst); Progenics (Inst) |